Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
作者： Joost C. M. Uitdehaag , Jeroen A. D. M. de Roos , Antoon M. van Doornmalen , Martine B. W. Prinsen , Jos de Man
DOI: 10.1371/JOURNAL.PONE.0092146
关键词:
摘要: … 2013) twenty-five kinase inhibitor drugs approved for clinical use… We discovered new drug sensitivity markers for MEK and EGFR … In lung smooth muscle cell line lines, the synthesis of β-…
harvard.edu
doaj.org参考文章(55)
Doriano Fabbro, Sandra W. Cowan-Jacob, Henrik Möbitz, Georg Martiny-Baron, Targeting cancer with small-molecular-weight kinase inhibitors. Methods of Molecular Biology. ,vol. 795, pp. 1- 34 ,(2012) , 10.1007/978-1-61779-337-0_1
Frauke Bentzien, Marcus Zuzow, Nathan Heald, Anna Gibson, Yongchang Shi, Leanne Goon, Peiwen Yu, Stefan Engst, Wentao Zhang, Donghui Huang, Lora Zhao, Valentina Vysotskaia, Felix Chu, Rajana Bautista, Belinda Cancilla, Peter Lamb, Alison H. Joly, F. Michael Yakes, In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid. ,vol. 23, pp. 1569- 1577 ,(2013) , 10.1089/THY.2013.0137
Joost CM Uitdehaag, Folkert Verkaar, Husam Alwan, Jos de Man, Rogier C Buijsman, Guido JR Zaman, A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets British Journal of Pharmacology. ,vol. 166, pp. 858- 876 ,(2012) , 10.1111/J.1476-5381.2012.01859.X
Daisuke Kitagawa, Koichi Yokota, Masaki Gouda, Yugo Narumi, Hiroshi Ohmoto, Eiji Nishiwaki, Kensaku Akita, Yasuyuki Kirii, Activity‐based kinase profiling of approved tyrosine kinase inhibitors Genes to Cells. ,vol. 18, pp. 110- 122 ,(2013) , 10.1111/GTC.12022
Scott M. Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A. Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer. ,vol. 129, pp. 245- 255 ,(2011) , 10.1002/IJC.25864
E. W. Joseph, C. A. Pratilas, P. I. Poulikakos, M. Tadi, W. Wang, B. S. Taylor, E. Halilovic, Y. Persaud, F. Xing, A. Viale, J. Tsai, P. B. Chapman, G. Bollag, D. B. Solit, N. Rosen, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 14903- 14908 ,(2010) , 10.1073/PNAS.1008990107
J. Colicelli, ABL tyrosine kinases: evolution of function, regulation, and specificity. Science Signaling. ,vol. 3, ,(2010) , 10.1126/SCISIGNAL.3139RE6
A. K. Jain, M. N. Murty, P. J. Flynn, Data clustering: a review ACM Computing Surveys. ,vol. 31, pp. 264- 323 ,(1999) , 10.1145/331499.331504
T.R. Chen, C.S. Dorotinsky, L.J. McGuire, M.L. Macy, R.J. Hay, DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin Cancer Genetics and Cytogenetics. ,vol. 81, pp. 103- 108 ,(1995) , 10.1016/0165-4608(94)00225-Z
Bissan Al-Lazikani, Mishal N. Patel, Mark D. Halling-Brown, Joseph E. Tym, Paul Workman, Objective assessment of cancer genes for drug discovery Nature Reviews Drug Discovery. ,vol. 12, pp. 35- 50 ,(2013) , 10.1038/NRD3913